Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, Room 144, Baltimore, MD 21231-1000, USA.
Breast Cancer Res Treat. 2012 Jan;131(2):709-11. doi: 10.1007/s10549-011-1859-6. Epub 2011 Nov 17.
We have prospectively tested the effects of simvastatin on the pharmacokinetics of anastrozole and on estrogen concentrations in postmenopausal women with hormone receptor-positive breast cancer who were receiving adjuvant anastrozole. Following 14 days of simvastatin, we did not observe a significant change in plasma concentrations of anastrozole or hydroxyanastrozole in nine evaluable women. Likewise, we did not observe any statistically significant change in serum concentrations of either estradiol, which remained in the undetectable range, or estrone sulfate. Simvastatin and anastrozole may be safely co-administered. Pharmacokinetic results suggest that simvastatin is not likely to compromise the activity of anastrozole.
我们前瞻性地研究了辛伐他汀对接受辅助阿那曲唑治疗的激素受体阳性乳腺癌绝经后妇女阿那曲唑及其羟基代谢物药代动力学的影响。在辛伐他汀治疗 14 天后，我们在 9 位可评估的患者中并未观察到阿那曲唑或羟基阿那曲唑的血药浓度有显著变化。同样，雌二醇和硫酸雌酮的血清浓度也未观察到任何统计学意义上的显著变化，两者均处于不可检测的范围。辛伐他汀和阿那曲唑可以安全联合使用。药代动力学结果表明辛伐他汀不太可能影响阿那曲唑的活性。
